Is Accutane Worth It? Results, Relapse and the Year-After View

    Is Accutane Worth It? Results, Relapse and the Year-After View

    Is Accutane worth it: 80% lesion reduction by week 20, 97% improved at one year, a third relapse, and who regrets it. The decision with trial numbers.

    Is Accutane Worth It? Results, Relapse and the Year-After View

    Is Accutane worth it is the question people ask after the dermatologist has offered it and before they have committed to five months of dry lips, monthly blood tests and, for women, the iPLEDGE schedule. The answer depends on what the acne is costing and what the alternatives have already failed to do, and both halves can be put in numbers. On the results side, 97% of patients in a 2013 JAMA Dermatology study reported their acne improved at one year, and the label describes a single course producing "complete and prolonged remission" in many patients. On the cost side, the side effects are predictable, mostly reversible and front-loaded, and the relapse rate, roughly a third within a year depending on dose, is the main reason some people are disappointed.

    This page lays out what a course buys, what it costs in side effects and effort, who gets the most from it, who tends to regret it, and what the people who have finished it say a year later. The before and after guide shows the results by month; this is the decision.

    Key takeaway: for severe, scarring or treatment-resistant acne, isotretinoin is the only treatment that regularly produces lasting remission, and most people who complete a full course say it was worth it. It is least worth it for mild acne that has not been given a fair trial of other treatments, and for anyone who cannot commit to the full cumulative dose, because a short or low course is the main predictor of relapse.

    What a Course Buys

    Accutane results in the trial and follow-up data

    Measure
    Figure
    Source

    Inflammatory lesion reduction at 20 weeks

    About 80% across dose groups

    Cochrane 2018 review of dose-comparison trials

    Patients reporting improvement at 12 months

    97.4%

    JAMA Dermatology 2013, 116 patients followed

    Relapse (any acne prescription) at 12 months

    32.7% overall; significantly lower above 220 mg/kg cumulative

    JAMA Dermatology 2013

    Retrial with a second isotretinoin course at 12 months

    1.7%

    JAMA Dermatology 2013

    Relapse over long-term follow-up (population study)

    41% received an acne prescription again; 26% had a second isotretinoin course

    British Journal of Dermatology 2007, 17,351 patients, 1984 to 2003

    Sebum still suppressed 80 weeks after stopping

    30 to 80% below baseline in 8 of 20 patients

    JAAD 1982

    The two relapse figures look different because they measure different things over different periods: the 2013 study counted relapse at one year after high-dose courses, the 2007 Quebec study counted any later acne prescription over up to two decades after courses given under older dosing. Both agree that most patients get a lasting result and a substantial minority need something more later, usually a topical rather than a second course.


    What It Costs

    The side effects are set out on the side effects page; the ones that matter for the decision are the near-certain ones (cheilitis, dry skin and eyes, some nosebleeds), the blood-test ones (triglycerides up markedly in about 25% of trial patients, reversible), the aches that affect anyone who lifts or runs, and the sun sensitivity that rules out beach holidays and laser. The effort cost is monthly appointments and labs, no blood donation, no vitamin A supplements, no tetracyclines, limited alcohol, and for women the contraception and pregnancy-test schedule. The money cost, with and without insurance, is in Accutane cost. The psychiatric warning applies to everyone and the evidence on it, no increased risk of depression in two meta-analyses, is in Accutane and depression. What it does not cost, on the evidence, is fertility, bowel disease or long-term organ damage at standard doses; is Accutane safe reviews those.


    Who Gets the Most From It

    Severe nodular or cystic acne, which is the label indication; acne that is scarring, because every month of active disease adds scars that isotretinoin cannot remove afterwards; acne that has failed a proper course of oral antibiotics plus topical retinoids; and truncal acne, which other treatments reach poorly. These patients have the most to gain and the clearest evidence. Adult women with hormonal jawline acne gain less reliably, because their acne is driven by a hormonal signal that returns when the glands regrow, which is why Accutane vs spironolactone exists as a comparison.


    Who Tends to Regret It

    Three groups. People with mild acne who took it as a shortcut and got the full side-effect course for a problem a retinoid cream might have handled; the label indication is severe disease, and the low-dose and microdosing approaches exist for the milder end. People who stopped early or ran a low cumulative dose and relapsed; the 2013 study and the label's own dose comparison both tie relapse to total exposure, so a course that is cut short delivers the side effects without the durability. And people who went in expecting it to fix scars, oiliness forever, or self-image; it treats active acne, and does Accutane help with scars explains what it does not do.


    The Year-After View

    Ask people a year out and the answer is mostly yes. The 2013 cohort's 97% improvement figure is self-reported satisfaction as much as a lesion count. The reasons given are consistent: the acne stopped being a daily problem, the scarring stopped, the antibiotics stopped, and the side effects that dominated the course faded within weeks of the last capsule. The minority who say no usually relapsed, had an unusually rough course, or did not need it in the first place. The r/Accutane threads summarised in Accutane Reddit tell the same story at larger volume. Whether it is worth it for a given person comes down to the two questions above: how severe is the acne, and will the full course be completed.

    For severe, scarring or treatment-resistant acne, yes on the evidence: about 80% lesion reduction by week 20, 97% of patients reporting improvement at one year, and lasting remission in most. For mild acne that has not tried other treatments, usually not.

    In the 2013 JAMA Dermatology follow-up, 97.4% reported their acne improved at 12 months. Relapse requiring any acne prescription was 32.7%, and only 1.7% needed a second isotretinoin course.

    Not for everyone. Most patients stay clear for years; around a third need some treatment again within a year, and a population study found 41% received an acne prescription again over long follow-up, 26% a second course.

    The label indication is severe nodular acne. For mild acne, dermatologists usually try topical retinoids and other options first; low-dose isotretinoin is sometimes used for persistent mild adult acne.

    Five months of dry lips, skin and eyes, monthly blood tests, raised triglycerides in about a quarter of patients, aches, sun sensitivity, and for women the iPLEDGE contraception and pregnancy-test schedule. Most of it reverses within weeks of stopping.

    Most people who finish a full course say yes because the side effects end with the course and the acne does not come back. The exceptions are people who stopped early, relapsed, or had mild acne to begin with.

    Accutane.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.

    E

    Editorial

    Author

    Published November 16, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    Advertising